cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced hematopoietic malignancies

Li, Yawen; Hamlin, Donald K.; Chyan, Ming-Kuan; Wong, Roger; Dorman, Eric F.; Emery, Robert C.; Woodle, Douglas R.; Manger, Ronald L.; Nartea, Margaret; Kenoyer, Aimee L.; Orozco, Johnnie J.; Green, Damian J.; Press, Oliver W.; Storb, Rainer; Sandmaier, Brenda M.; Wilbur, D. Scott; Fassbender, ed., Michael Ernst-Heinrich

doi:10.1371/journal.pone.0205135

Title: cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced hematopoietic malignancies

Journal Article · 17 October 2018 · PLoS ONE

DOI: https://doi.org/10.1371/journal.pone.0205135 · OSTI ID:1478137

Li, Yawen; Hamlin, Donald K.; Chyan, Ming-Kuan; Wong, Roger; Dorman, Eric F.; Emery, Robert C.; Woodle, Douglas R.; Manger, Ronald L.; Nartea, Margaret; Kenoyer, Aimee L.; Orozco, Johnnie J.; Green, Damian J.; Press, Oliver W.; Storb, Rainer; Sandmaier, Brenda M.;

; Fassbender, ed., Michael Ernst-Heinrich

Not Available

View Journal Article

Cite

Export

Save

Research Organization:: Univ. of Washington, Seattle, WA (United States)

Sponsoring Organization:: USDOE Office of Science (SC), Nuclear Physics (NP); USDOE Office of Science (SC), Nuclear Physics (NP) (SC-26)

Grant/Contract Number:: SC0013618

OSTI ID:: 1478137

Journal Information:: PLoS ONE, Journal Name: PLoS ONE Journal Issue: 10 Vol. 13; ISSN 1932-6203

Publisher:: Public Library of Science (PLoS)Copyright Statement

Country of Publication:: United States

Language:: English

References (20)

Design and evaluation of an external high-current target for production of ²¹¹ At Gagnon, K.; Risler, R.; Pal, S. Journal of Labelled Compounds and Radiopharmaceuticals, Vol. 55, Issue 12 https://doi.org/10.1002/jlcr.2968	journal	October 2012
Radioimmunotherapy with alpha-emitting nuclides McDevitt, Michael R.; Sgouros, George; Finn, Ronald D. European Journal of Nuclear Medicine and Molecular Imaging, Vol. 25, Issue 9 https://doi.org/10.1007/s002590050306	journal	September 1998
Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas Press, O. W.; Appelbaum, F.; Martin, P. J. The Lancet, Vol. 346, Issue 8971 https://doi.org/10.1016/S0140-6736(95)92225-3	journal	August 1995
Alpha-particles for targeted therapy Sgouros, George Advanced Drug Delivery Reviews, Vol. 60, Issue 12 https://doi.org/10.1016/j.addr.2008.04.007	journal	September 2008
Preparation and in vivo evaluation of radioiodinated closo-decaborate(2-) derivatives to identify structural components that provide low retention in tissues Wilbur, D. Scott; Chyan, Ming-Kuan; Hamlin, Donald K. Nuclear Medicine and Biology, Vol. 37, Issue 2 https://doi.org/10.1016/j.nucmedbio.2009.10.004	journal	February 2010
Reagents for Astatination of Biomolecules. 2. Conjugation of Anionic Boron Cage Pendant Groups to a Protein Provides a Method for Direct Labeling that is Stable to in Vivo Deastatination Wilbur, D. Scott; Chyan, Ming-Kuan; Hamlin, Donald K. Bioconjugate Chemistry, Vol. 18, Issue 4 https://doi.org/10.1021/bc060345s	journal	July 2007
Reagents for Astatination of Biomolecules. 6. An Intact Antibody Conjugated with a Maleimido- closo -Decaborate(2-) Reagent via Sulfhydryl Groups Had Considerably Higher Kidney Concentrations than the Same Antibody Conjugated with an Isothiocyanato- closo -Decaborate(2-) Reagent via Lysine Amines Wilbur, D. Scott; Chyan, Ming-Kuan; Nakamae, Hirohisa Bioconjugate Chemistry, Vol. 23, Issue 3 https://doi.org/10.1021/bc200401b	journal	February 2012
Reagents for Astatination of Biomolecules. 3. Comparison of closo -Decaborate(2-) and closo -Dodecaborate(2-) Moieties as Reactive Groups for Labeling with Astatine-211 Wilbur, D. Scott; Chyan, Ming-Kuan; Hamlin, Donald K. Bioconjugate Chemistry, Vol. 20, Issue 3 https://doi.org/10.1021/bc800515d	journal	March 2009
Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support Press, Oliver W.; Eary, Janet F.; Appelbaum, Frederick R. New England Journal of Medicine, Vol. 329, Issue 17 https://doi.org/10.1056/NEJM199310213291702	journal	October 1993
Biodistributions, Myelosuppression, and Toxicities in Mice Treated with an Anti-CD45 Antibody Labeled with the -Emitting Radionuclides Bismuth-213 or Astatine-211 Nakamae, H.; Wilbur, D. S.; Hamlin, D. K. Cancer Research, Vol. 69, Issue 6 https://doi.org/10.1158/0008-5472.CAN-08-4363	journal	February 2009
131I–anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission Pagel, John M.; Appelbaum, Frederick R.; Eary, Janet F. Blood, Vol. 107, Issue 5 https://doi.org/10.1182/blood-2005-06-2317	journal	March 2006
Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211–labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation Chen, Yun; Kornblit, Brian; Hamlin, Donald K. Blood, Vol. 119, Issue 5 https://doi.org/10.1182/blood-2011-09-380436	journal	February 2012
Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model Orozco, Johnnie J.; Bäck, Tom; Kenoyer, Aimee Blood, Vol. 121, Issue 18 https://doi.org/10.1182/blood-2012-11-467035	journal	May 2013
Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation Matthews, Dc; Appelbaum, Fr; Eary, Jf Blood, Vol. 85, Issue 4 https://doi.org/10.1182/blood.V85.4.1122.bloodjournal8541122	journal	February 1995
Phase I Study of 131I-Anti-CD45 Antibody Plus Cyclophosphamide and Total Body Irradiation for Advanced Acute Leukemia and Myelodysplastic Syndrome Matthews, Dana C.; Appelbaum, Frederick R.; Eary, Janet F. Blood, Vol. 94, Issue 4 https://doi.org/10.1182/blood.V94.4.1237	journal	August 1999
Chemical and Radiochemical Considerations in Radiolabeling with α-Emitting Radionuclides Scott Wilbur, D. Current Radiopharmaceuticalse, Vol. 4, Issue 3 https://doi.org/10.2174/1874471011104030214	journal	July 2011
Clinical Experience with -Particle Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6 Zalutsky, M. R.; Reardon, D. A.; Akabani, G. Journal of Nuclear Medicine, Vol. 49, Issue 1 https://doi.org/10.2967/jnumed.107.046938	journal	December 2007
Intraperitoneal -Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab')2--A Phase I Study Andersson, H.; Cederkrantz, E.; Back, T. Journal of Nuclear Medicine, Vol. 50, Issue 7 https://doi.org/10.2967/jnumed.109.062604	journal	June 2009
Accumulation of Astatine211 by Thyroid Gland in Man. Hamilton, J. G.; Durbin, P. W.; Parrott, M. W. Experimental Biology and Medicine, Vol. 86, Issue 2 https://doi.org/10.3181/00379727-86-21100	journal	June 1954
Evaluation of a Wet Chemistry Method for Isolation of Cyclotron Produced [211At]Astatine Balkin, Ethan; Hamlin, Donald; Gagnon, Katherine Applied Sciences, Vol. 3, Issue 3 https://doi.org/10.3390/app3030636	journal	September 2013